Tuesday, June 02, 2020 1:07:42 PM
I’m BULLISH NOW - they now know dosage....they will tweak and work with FDA....this price is a gift
64 mg dose was statistically significantly different from placebo as measured by change in PSP at all other assessment timepoints (Week 4, nominal p ≤0.005, ES=0.3; Week 8: nominal p ≤0.018, ES=0.3).
“The substantial improvements in the PSP scale with the 64 mg dose are tremendously encouraging. These study results represent a very important outcome in a study of a potential treatment of negative symptoms, one of the most important drivers of everyday disability and a critical unmet medical need for patients with schizophrenia. The consistency in treatment effects, in terms of overall negative symptoms and of the most important subtype, reduced emotional experience, between the previous Phase 2b study and the current one is encouraging. The increased placebo effect from the first to second study seems to be the only reason that the study did not meet its primary endpoint.”
Recent NERV News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 08:05:53 PM
- Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 11:01:13 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:25:30 PM
- Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates • GlobeNewswire Inc. • 05/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 01:04:42 PM
- Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia • GlobeNewswire Inc. • 02/27/2024 01:00:00 PM
- Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 11:30:30 AM
- Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates • GlobeNewswire Inc. • 11/07/2023 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 12:00:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/05/2023 08:34:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/05/2023 08:33:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/29/2023 12:58:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/29/2023 12:57:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/28/2023 08:05:53 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM